2021 IPO

Impel NeuroPharma Stock

Medical device company developing a direct nose-to-brain delivery

Sign up today and learn more about Impel NeuroPharma Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Impel NeuroPharma Stock

Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery.

Funding History

January 2010$305K
October 2011$500K
August 2012$25K
November 2013$2.6M
October 2015$0
August 2016$1.1M
December 2016$36.0M
December 2018$67.5M


Chief Business Officer

Richard Haiduck

Director of R&D

Alan Brunelle

Co-Founder & CEO

Michael Hite

Co-Founder & Chief Scientific Officer

John Hoekman

President & CEO

Jon Congleton

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: